PEX is a dubious disease in the field of genetic metabolism, clinical performance is complex and often involves multi-system fatigue. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in linking a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, significant improvements have been made in many previously difficult-to-treat genetic metabolic disorders. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely scheduling according to disease changes.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of PEX for oxidase enzyme bioavailability disorder. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.